晚期帕金森病患者的莱沃多巴处方模式:一项日本数据库分析
Atsushi Takeda1,2, Toru Baba1, Jun Watanabe3
1Department of Neurology, National Hospital Organization Sendai Nishitaga Hospital, 2-11-11 Kagitorihoncho, Taihaku-ku, Sendai 982-8555, Japan.
Parkinson's disease
|October 6, 2023
概括
日本患有晚期帕金森病 (PD) 的患者通常接受的利沃多巴剂量低于推剂量. 这项研究发现,许多人可以从更高的利沃多巴剂量中受益,以便进行更密集的治疗.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 在日本,对于晚期帕金森病 (PD) 的利沃多巴剂量通常低于美国或欧洲.
- 日本PD指导方针建议随着疾病的进展,增加勒沃多巴剂量.
- 有限的临床数据存在于日本的晚期PD患者的利沃多巴处方模式.
研究的目的:
- 为了分析日本晚期PD住院患者的列沃多巴处方模式.
- 将处方的乐伏多巴剂量与国际标准和日本指导方针进行比较.
- 为了确定这个人群中更强烈的勒沃多巴治疗的潜力.
主要方法:
- 使用日本索赔数据 (医疗数据视觉公司) 的回顾性观察研究.
- 纳入标准:晚期PD (定义为权利要求和日常生活活动得分<60).
- 在指数住院和随着时间的推移,分析勒沃多巴和同时使用的PD/非PD药物剂量.
主要成果:
- 分析了4029名患有晚期PD的患者 (平均年龄为76.9岁).
- 在指数住院期间,中位数列伏多巴剂量为418.2毫克/天 (9.0毫克/千克/天).
- 在指数日期之前和之后的5年里,Levodopa的剂量保持相对稳定,这表明剂量不足.
结论:
- 许多患有晚期PD的日本患者可能未能接受利沃多巴的治疗.
- 更高的勒沃多巴剂量可能会提供更密集和更有效的治疗.
- 对日本晚期PD最佳剂量策略的进一步研究是有必要的.
相关概念视频
01:24Parkinson's Disease: Treatment
287
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
287
01:15Parkinson's Disease: Overview
587
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
587
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
358
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
358
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.2K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.2K
01:28Drug Therapy
51
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
51
01:37Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K